2496.Hk
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotech products and services.
Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotech products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotech products and services.
The company's capital structure is characterized by a negative total equity of CNY -53,029,000 and a debt-to-equity ratio of -2.41, indicating a significant reliance on debt financing and a lack of equity cushion. Despite holding CNY 100,065,000 in cash and equivalents, the company's liquidity is rated as medium due to its negative net cash position after subtracting total debt. The current ratio of 0.66 further underscores the company's limited ability to meet short-term obligations with its current assets.
Profitability metrics reveal a challenging financial position. The company reported a net loss of CNY 84,732,000 and an operating loss of CNY 79,779,000, with a return on assets of -0.4842, indicating that the company is not generating returns that cover its asset base. The return on equity of 1.5978 is also concerning, as it suggests that the company is not effectively utilizing its equity to generate profits.
The company's revenue is not segmented by product or geographic region in the available data, making it difficult to assess the concentration of its revenue streams. However, the lack of detailed segment information limits the ability to evaluate the diversification of its business operations.
The company's growth trajectory is uncertain, as it has reported a net loss and negative operating cash flow. The absence of positive revenue growth or improvement in profitability metrics suggests that the company may face challenges in achieving sustainable growth in the near term.
Risk factors include a high level of debt and negative equity, which could limit the company's financial flexibility and increase its vulnerability to economic downturns. The company's dilution potential is rated as low, but the negative equity position and reliance on debt financing could lead to further dilution if the company needs to raise additional capital.
Recent events and filings have not been disclosed in the available data, so there is no information on specific events that may have impacted the company's financial performance or strategic direction.
- The company is operating at a net loss and has a negative equity position, indicating significant financial distress.
- The company's liquidity is constrained by a negative net cash position and a current ratio below 1.
- The company's profitability metrics are negative, suggesting poor operational performance.
- The company's growth trajectory is uncertain due to its financial challenges.
- The company's risk profile is elevated due to high debt and negative equity.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 2496.HK Market data — financials · 2026-05-26